These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 6389777

  • 21. Adoptive immunotherapy of cancer: accomplishments and prospects.
    Rosenberg SA.
    Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N, Tanaka R, Yoshida S, Hara N, Saito T.
    Cancer Res; 1988 Apr 15; 48(8):2047-52. PubMed ID: 3258182
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
    Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA.
    J Immunol; 1986 Dec 01; 137(11):3675-80. PubMed ID: 3491145
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ, Yang JC, Afreniere RL, Shu SY, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):285-94. PubMed ID: 3108401
    [Abstract] [Full Text] [Related]

  • 31. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB.
    Cancer Res; 1988 Jun 15; 48(12):3461-9. PubMed ID: 3259468
    [Abstract] [Full Text] [Related]

  • 32. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA.
    Cancer Res; 1988 Aug 01; 48(15):4409-16. PubMed ID: 3260537
    [Abstract] [Full Text] [Related]

  • 33. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
    Rosenberg SA, Eberlein TJ, Grimm EA, Lotze MT, Mazumder A, Rosenstein M.
    Surgery; 1982 Aug 01; 92(2):328-36. PubMed ID: 6980492
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S, Rosenberg SA.
    J Immunol; 1985 Oct 01; 135(4):2895-903. PubMed ID: 2411817
    [Abstract] [Full Text] [Related]

  • 39. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases.
    Sherwood ER, Williams DL, McNamee RB, Jones EL, Browder IW, Di Luzio NR.
    J Biol Response Mod; 1988 Apr 01; 7(2):185-98. PubMed ID: 3283299
    [Abstract] [Full Text] [Related]

  • 40. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
    Shu S, Chou T, Rosenberg SA.
    Cancer Res; 1987 Mar 01; 47(5):1354-60. PubMed ID: 3102046
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.